72eb75ba
2021-10-27
Ok
Cortexyme's Alzheimer's treatment fails to meet main goals in study<blockquote>Cortexyme的阿尔茨海默病治疗未能达到研究的主要目标</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":855930165,"tweetId":"855930165","gmtCreate":1635322775201,"gmtModify":1635322775273,"author":{"id":4092523560597200,"idStr":"4092523560597200","authorId":4092523560597200,"authorIdStr":"4092523560597200","name":"72eb75ba","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/855930165","repostId":1123295835,"repostType":4,"repost":{"id":"1123295835","kind":"news","pubTimestamp":1635322546,"share":"https://www.laohu8.com/m/news/1123295835?lang=zh_CN&edition=full","pubTime":"2021-10-27 16:15","market":"us","language":"en","title":"Cortexyme's Alzheimer's treatment fails to meet main goals in study<blockquote>Cortexyme的阿尔茨海默病治疗未能达到研究的主要目标</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123295835","media":"Reuters","summary":"Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet th","content":"<p>Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer's disease in a study.</p><p><blockquote>路透10月26日-Cortexyme Inc(CRTX.O)周二表示，在一项研究中，其实验性口服药丸未能达到改善轻中度阿尔茨海默病患者认知和功能能力的主要目标。</blockquote></p><p> The drug, atuzaginstat, is designed to target the P. gingivalis bacteria found in the brain of patients suffering from the memory robbing disease.</p><p><blockquote>这种名为atuzaginstat的药物旨在针对记忆剥夺病患者大脑中发现的牙龈卟啉单胞菌。</blockquote></p><p> The mid-to-late stage study tested 643 patients and did not meet statistical significance in its goals, according to two scales measuring disease progression.</p><p><blockquote>根据两种测量疾病进展的量表，中后期研究测试了643名患者，未达到其目标的统计学显著性。</blockquote></p><p> In a group of patients with the bacteria detected in their saliva, the drug showed 57% slowing of cognitive decline on a commonly used test but failed to show significant benefits on another scale, which is generally filled out by a patient's caregiver.</p><p><blockquote>在一组唾液中检测到细菌的患者中，该药物在一项常用测试中显示认知能力下降减缓了57%，但在另一项通常由患者的护理人员填写的量表上未能显示出显著的益处。</blockquote></p><p> However, Cortexyme said the pill led to a reduction in the bacteria, which was associated with some improved outcomes at the end of the treatment period under the study. It plans to report the data to regulators to determine the path forward for the drug.</p><p><blockquote>然而，Cortexyme表示，这种药丸导致细菌减少，这与研究治疗期结束时的一些改善结果有关。它计划向监管机构报告数据，以确定该药物的发展方向。</blockquote></p><p> Alzheimer's treatments have come into focus since the U.S. health regulator approved Biogen's(BIIB.O)controversial drug Aduhelm in June. The drug is used to treat early stages of the disease.</p><p><blockquote>自美国卫生监管机构批准百健（Biogen）（BIIB）的争议药物Aduhelm以来，阿尔茨海默氏症的治疗已成为人们关注的焦点。这种药物用于治疗疾病的早期阶段。</blockquote></p><p> \"There's nothing that is approved for treating the really sick patients with mild-to-moderate disease, which is where we've shown an effect,\" said Cortexyme's chief medical officer Michael Detke.</p><p><blockquote>Cortexyme首席医疗官Michael Detke表示：“没有任何药物被批准用于治疗患有轻度至中度疾病的真正患者，而这正是我们显示出效果的地方。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cortexyme's Alzheimer's treatment fails to meet main goals in study<blockquote>Cortexyme的阿尔茨海默病治疗未能达到研究的主要目标</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCortexyme's Alzheimer's treatment fails to meet main goals in study<blockquote>Cortexyme的阿尔茨海默病治疗未能达到研究的主要目标</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-10-27 16:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer's disease in a study.</p><p><blockquote>路透10月26日-Cortexyme Inc(CRTX.O)周二表示，在一项研究中，其实验性口服药丸未能达到改善轻中度阿尔茨海默病患者认知和功能能力的主要目标。</blockquote></p><p> The drug, atuzaginstat, is designed to target the P. gingivalis bacteria found in the brain of patients suffering from the memory robbing disease.</p><p><blockquote>这种名为atuzaginstat的药物旨在针对记忆剥夺病患者大脑中发现的牙龈卟啉单胞菌。</blockquote></p><p> The mid-to-late stage study tested 643 patients and did not meet statistical significance in its goals, according to two scales measuring disease progression.</p><p><blockquote>根据两种测量疾病进展的量表，中后期研究测试了643名患者，未达到其目标的统计学显著性。</blockquote></p><p> In a group of patients with the bacteria detected in their saliva, the drug showed 57% slowing of cognitive decline on a commonly used test but failed to show significant benefits on another scale, which is generally filled out by a patient's caregiver.</p><p><blockquote>在一组唾液中检测到细菌的患者中，该药物在一项常用测试中显示认知能力下降减缓了57%，但在另一项通常由患者的护理人员填写的量表上未能显示出显著的益处。</blockquote></p><p> However, Cortexyme said the pill led to a reduction in the bacteria, which was associated with some improved outcomes at the end of the treatment period under the study. It plans to report the data to regulators to determine the path forward for the drug.</p><p><blockquote>然而，Cortexyme表示，这种药丸导致细菌减少，这与研究治疗期结束时的一些改善结果有关。它计划向监管机构报告数据，以确定该药物的发展方向。</blockquote></p><p> Alzheimer's treatments have come into focus since the U.S. health regulator approved Biogen's(BIIB.O)controversial drug Aduhelm in June. The drug is used to treat early stages of the disease.</p><p><blockquote>自美国卫生监管机构批准百健（Biogen）（BIIB）的争议药物Aduhelm以来，阿尔茨海默氏症的治疗已成为人们关注的焦点。这种药物用于治疗疾病的早期阶段。</blockquote></p><p> \"There's nothing that is approved for treating the really sick patients with mild-to-moderate disease, which is where we've shown an effect,\" said Cortexyme's chief medical officer Michael Detke.</p><p><blockquote>Cortexyme首席医疗官Michael Detke表示：“没有任何药物被批准用于治疗患有轻度至中度疾病的真正患者，而这正是我们显示出效果的地方。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/cortexymes-alzheimers-treatment-fails-meet-main-goals-study-2021-10-26/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/cortexymes-alzheimers-treatment-fails-meet-main-goals-study-2021-10-26/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123295835","content_text":"Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer's disease in a study.\nThe drug, atuzaginstat, is designed to target the P. gingivalis bacteria found in the brain of patients suffering from the memory robbing disease.\nThe mid-to-late stage study tested 643 patients and did not meet statistical significance in its goals, according to two scales measuring disease progression.\nIn a group of patients with the bacteria detected in their saliva, the drug showed 57% slowing of cognitive decline on a commonly used test but failed to show significant benefits on another scale, which is generally filled out by a patient's caregiver.\nHowever, Cortexyme said the pill led to a reduction in the bacteria, which was associated with some improved outcomes at the end of the treatment period under the study. It plans to report the data to regulators to determine the path forward for the drug.\nAlzheimer's treatments have come into focus since the U.S. health regulator approved Biogen's(BIIB.O)controversial drug Aduhelm in June. The drug is used to treat early stages of the disease.\n\"There's nothing that is approved for treating the really sick patients with mild-to-moderate disease, which is where we've shown an effect,\" said Cortexyme's chief medical officer Michael Detke.","news_type":1,"symbols_score_info":{"CRTX":0.9}},"isVote":1,"tweetType":1,"viewCount":764,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/855930165"}
精彩评论